$145 million pharma acquisition to help launch opioid overdose drug
Indivior’s $145 million acquisition of Opiant Pharmaceuticals will support the…
Indivior’s $145 million acquisition of Opiant Pharmaceuticals will support the launch of OPNT003, an opioid overdose reversal agent.